IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis
Abstract
:1. Introduction
2. Material and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Badri, T.; Kumar, P.; Oakley, A.M. Plaque Psoriasis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2024. Available online: http://www.ncbi.nlm.nih.gov/books/NBK430879/ (accessed on 17 July 2024).
- Kirsten, N.; Rustenbach, S.; von Kiedrowski, R.; Sorbe, C.; Reich, K.; Augustin, M. Which PASI Outcome Is Most Relevant to the Patients in Real-World Care? Life 2021, 11, 1151. [Google Scholar] [CrossRef] [PubMed]
- Nast, A.; Sporbeck, B.; Rosumeck, S.; Pathirana, D.; Jacobs, A.; Werner, R.N.; Schmitt, J. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J. Investig. Dermatol. 2013, 133, 1963–1970. [Google Scholar] [CrossRef] [PubMed]
- Egeberg, A.; Andersen, Y.M.F.; Halling-Overgaard, A.; Alignahi, F.; Thyssen, J.P.; Burge, R.; Mallbris, L. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 39–46. [Google Scholar] [CrossRef] [PubMed]
- Yao, C.J.; Lebwohl, M.G. Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update. J. Drugs Dermatol. 2019, 18, 229–233. [Google Scholar]
- Rouse, B.; Chaimani, A.; Li, T. Network meta-analysis: An introduction for clinicians. Intern. Emerg. Med. 2017, 12, 103–111. [Google Scholar] [CrossRef] [PubMed]
- MEDLINE PubMED. PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/ (accessed on 3 April 2024).
- Ankit Rohatgi. automeris.io. WebPlotDigitizer Version 4.7. Available online: https://automeris.io/WebPlotDigitizer.html (accessed on 3 April 2024).
- Owen, R.K.; Bradbury, N.; Xin, Y.; Cooper, N.; Sutton, A. MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta. Res. Synth. Methods 2019, 10, 569–581. [Google Scholar] [CrossRef]
- Nevill, C.R.; Cooper, N.J.; Sutton, A.J. A multifaceted graphical display, including treatment ranking, was developed to aid interpretation of network meta-analysis. J. Clin. Epidemiol. 2023, 157, 83–91. [Google Scholar] [CrossRef] [PubMed]
- Hackenberger, B.K. Bayesian meta-analysis now—Let’s do it. Croat. Med. J. 2020, 61, 564–568. [Google Scholar] [CrossRef]
- Liu, Y.; Béliveau, A.; Wei, Y.; Chen, M.Y.; Record-Lemon, R.; Kuo, P.-L.; Pritchard, E.; Tang, X.; Chen, G. A Gentle Introduction to Bayesian Network Meta-Analysis Using an Automated R Package. Multivar. Behav. Res. 2023, 58, 706–722. [Google Scholar] [CrossRef]
- Bagel, J.; Blauvelt, A.; Nia, J.; Hashim, P.; Patekar, M.; de Vera, A.; Ahmad, K.; Paguet, B.; Xia, S.; Muscianisi, E.; et al. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). J. Eur. Acad. Dermatol. Venereol. 2021, 35, 135–142. [Google Scholar] [CrossRef]
- Blauvelt, A.; Reich, K.; Tsai, T.-F.; Tyring, S.; Vanaclocha, F.; Kingo, K.; Ziv, M.; Pinter, A.; Vender, R.; Hugot, S.; et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J. Am. Acad. Dermatol. 2017, 76, 60–69.e9. [Google Scholar] [CrossRef] [PubMed]
- Blauvelt, A.; Papp, K.A.; Griffiths, C.E.; Randazzo, B.; Wasfi, Y.; Shen, Y.-K.; Li, S.; Kimball, A.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am. Acad. Dermatol. 2017, 76, 405–417. [Google Scholar] [CrossRef] [PubMed]
- Blauvelt, A.; Leonardi, C.; Elewski, B.; Crowley, J.; Guenther, L.; Gooderham, M.; Langley, R.; Vender, R.; Pinter, A.; Griffiths, C.; et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br. J. Dermatol. 2021, 184, 1047–1058. [Google Scholar] [CrossRef] [PubMed]
- de Vries, A.; Thio, H.; de Kort, W.; Opmeer, B.; van der Stok, H.; de Jong, E.; Horvath, B.; Busschbach, J.; Nijsten, T.; Spuls, P. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: The Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study. Br. J. Dermatol. 2017, 176, 624–633. [Google Scholar] [CrossRef]
- Gordon, K.B.; Duffin, K.C.; Bissonnette, R.; Prinz, J.C.; Wasfi, Y.; Li, S.; Shen, Y.-K.; Szapary, P.; Randazzo, B.; Reich, K. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N. Engl. J. Med. 2015, 373, 136–144. [Google Scholar] [CrossRef]
- Gordon, K.B.; Strober, B.; Lebwohl, M.; Augustin, M.; Blauvelt, A.; Poulin, Y.; Papp, K.A.; Sofen, H.; Puig, L.; Foley, P.; et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018, 392, 650–661. [Google Scholar] [CrossRef]
- Griffiths, C.E.M.; Reich, K.; Lebwohl, M.; van de Kerkhof, P.; Paul, C.; Menter, A.; Cameron, G.S.; Erickson, J.; Zhang, L.; Secrest, R.J.; et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials. Lancet 2015, 386, 541–551. [Google Scholar] [CrossRef]
- Langley, R.G.; Elewski, B.E.; Lebwohl, M.; Reich, K.; Griffiths, C.E.; Papp, K.; Puig, L.; Nakagawa, H.; Spelman, L.; Sigurgeirsson, B.; et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N. Engl. J. Med. 2014, 371, 326–338. [Google Scholar] [CrossRef] [PubMed]
- Lebwohl, M.; Strober, B.; Menter, A.; Gordon, K.; Weglowska, J.; Puig, L.; Papp, K.; Spelman, L.; Toth, D.; Kerdel, F.; et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N. Engl. J. Med. 2015, 373, 1318–1328. [Google Scholar] [CrossRef]
- Lebwohl, M.; Blauvelt, A.; Paul, C.; Sofen, H.; Węgłowska, J.; Piguet, V.; Burge, D.; Rolleri, R.; Drew, J.; Peterson, L.; et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J. Am. Acad. Dermatol. 2018, 79, 266–276.e5. [Google Scholar] [CrossRef]
- Reich, K.; Armstrong, A.W.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Li, S.; Shen, Y.-K.; Gordon, K.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J. Am. Acad. Dermatol. 2017, 76, 418–431. [Google Scholar] [CrossRef]
- Reich, K.; Pinter, A.; Lacour, J.; Ferrandiz, C.; Micali, G.; French, L.; Lomaga, M.; Dutronc, Y.; Henneges, C.; Wilhelm, S.; et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br. J. Dermatol. 2017, 177, 1014–1023. [Google Scholar] [CrossRef] [PubMed]
- Reich, K.; Papp, K.A.; Blauvelt, A.; Tyring, S.K.; Sinclair, R.; Thaçi, D.; Nograles, K.; Mehta, A.; Cichanowitz, N.; Li, Q.; et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials. Lancet 2017, 390, 276–288. [Google Scholar] [CrossRef]
- Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br. J. Dermatol. 2020, 182, 869–879. [Google Scholar] [CrossRef] [PubMed]
- Reich, K.; Papp, K.A.; Blauvelt, A.; Langley, R.G.; Armstrong, A.; Warren, R.B.; Gordon, K.B.; Merola, J.F.; Okubo, Y.; Madden, C.; et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet 2021, 397, 487–498. [Google Scholar] [CrossRef] [PubMed]
- Reich, K.; Warren, R.B.; Lebwohl, M.; Gooderham, M.; Strober, B.; Langley, R.G.; Paul, C.; De Cuyper, D.; Vanvoorden, V.; Madden, C.; et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N. Engl. J. Med. 2021, 385, 142–152. [Google Scholar] [CrossRef] [PubMed]
- Reich, K.; Armstrong, A.W.; Langley, R.G.; Flavin, S.; Randazzo, B.; Li, S.; Hsu, M.-C.; Branigan, P.; Blauvelt, A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. Lancet 2019, 394, 831–839. [Google Scholar] [CrossRef]
- Warren, R.; Blauvelt, A.; Poulin, Y.; Beeck, S.; Kelly, M.; Wu, T.; Geng, Z.; Paul, C. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br. J. Dermatol. 2021, 184, 50–59. [Google Scholar] [CrossRef] [PubMed]
- Warren, R.B.; Blauvelt, A.; Bagel, J.; Papp, K.A.; Yamauchi, P.; Armstrong, A.; Langley, R.G.; Vanvoorden, V.; De Cuyper, D.; Cioffi, C.; et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N. Engl. J. Med. 2021, 385, 130–141. [Google Scholar] [CrossRef]
- Mosca, M.; Hong, J.; Hadeler, E.; Hakimi, M.; Liao, W.; Bhutani, T. The Role of IL-17 Cytokines in Psoriasis. Immunotargets Ther. 2021, 10, 409–418. [Google Scholar] [CrossRef] [PubMed]
- Brembilla, N.C.; Boehncke, W.H. Revisiting the interleukin 17 family of cytokines in psoriasis: Pathogenesis and potential targets for innovative therapies. Front. Immunol. 2023, 14, 1186455. [Google Scholar] [CrossRef] [PubMed]
- Cote, M.P.; Lubowitz, J.H.; Brand, J.C.; Rossi, M.J. Understanding Network Meta-analysis (NMA) Conclusions Requires Scrutiny of Methods and Results: Introduction to NMA and the Geometry of Evidence. Arthroscopy 2021, 37, 2013–2016. [Google Scholar] [CrossRef]
Authors | Article Title | Met Criteria for PASI75 Analysis | Met Criteria for PASI90 Analysis |
---|---|---|---|
Bagel et al. [13] | Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) | Yes | Yes |
Blauvelt et al. [14] | Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study | Yes | Yes |
Blauvelt et al. [15] | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial | Yes | Yes |
Blauvelt et al. [16] | A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial | Yes | Yes |
de Vries et al. [17] | A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study | Yes | No |
Gordon et al. [18] | A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis | Yes | No |
Gordon et al. [19] | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials | No | Yes |
Gordon et al. [19] | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials | No | Yes |
Griffiths et al. [20] | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials | Yes | No |
Langley et al. [21] | Secukinumab in plaque psoriasis--results of two phase 3 trials | Yes | No |
Lebwohl et al. [22] | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis (AMAGINE-2) | Yes | No |
Lebwohl et al. [22] | Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis (AMAGINE-3) | Yes | No |
Lebwohl et al. [23] | Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT) | Yes | No |
Reich et al. [24] | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial | Yes | Yes |
Reich et al. [25] | Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study | Yes | Yes |
Reich et al. [26] | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials | Yes | No |
Reich et al. [27] | A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment | Yes | No |
Reich et al. [28] | Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial | Yes | Yes |
Reich et al. [29] | Bimekizumab versus Secukinumab in Plaque Psoriasis | Yes | Yes |
Reich et al. [30] | Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial | No | Yes |
Warren et al. [31] | Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial | Yes | Yes |
Warren et al. [32] | Bimekizumab versus Adalimumab in Plaque Psoriasis | Yes | Yes |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aggarwal, P.; Fleischer, A.B., Jr. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis. J. Clin. Med. 2024, 13, 5139. https://doi.org/10.3390/jcm13175139
Aggarwal P, Fleischer AB Jr. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis. Journal of Clinical Medicine. 2024; 13(17):5139. https://doi.org/10.3390/jcm13175139
Chicago/Turabian StyleAggarwal, Pushkar, and Alan B. Fleischer, Jr. 2024. "IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis" Journal of Clinical Medicine 13, no. 17: 5139. https://doi.org/10.3390/jcm13175139